Ozempic is not likely to directly enlarge the male appendage.

A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.

Eli Lilly's big Summer 2025 update

We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.

Semaglutide vs Tirzepatide (Clinical trial)

Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.

Roche and Carmot's GLP1 pipeline

We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.

A new risk: Kidney Cancer

New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.

GLP1s vs. Addiction, a quick review

We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.

An update on Retatrutide (May 2025)

We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.

GLP1s lower inflammation, Psoriasis, AND increase fertility?

We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.

GLP1s and Tariffs, the story so far

We take a look at the various movements in GLP1 policy by the Trump administration, so far.

Wegovy in pill form is coming

Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.

Boosting Tirzepatide with Nimacimab

Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.

Eli Lilly suing GLP1 compounders & related companies

Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.